332013-43-1

Basic information

• Product Name: (2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL
• Synonyms: (2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL;4-(HYDROXYMETHYL)-N-METHYLPYRIDINE-2-CARBOXAMIDE;2-Pyridinecarboxamide, 4-(hydroxymethyl)-N-methyl-
• CAS NO: 332013-43-1
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.18
• Mol File: 332013-43-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 400.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.214±0.06 g/cm3(Predicted)
• PKA: 13.16±0.10(Predicted)
• CAS DataBase Reference: (2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL(332013-43-1)
• EPA Substance Registry System: (2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL(332013-43-1)

Safety Data

• Hazardous Substances Data: 332013-43-1(Hazardous Substances Data)

Usage

Description

(2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL is a chemical compound that features a pyridine ring with a methylamino carbonyl group and a hydroxymethyl group attached to it. It serves as a versatile building block in the synthesis of pharmaceuticals and other organic compounds, with potential applications in the pharmaceutical industry due to its ability to act as an intermediate in the production of various drugs and biologically active molecules.

Uses

Used in Pharmaceutical Industry:
(2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL is used as a building block for the synthesis of various pharmaceuticals and biologically active molecules, contributing to the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
(2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL is used as a reagent in organic synthesis, facilitating the creation of a range of chemical compounds for various applications.
Used in Preparation of Other Chemical Compounds:
(2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL is used as a precursor in the preparation of other chemical compounds, expanding its utility in the chemical industry.
It is crucial to handle (2-METHYLAMINOCARBONYL-4-PYRIDYL)METHANOL with care and adhere to proper safety protocols to avoid potential health hazards associated with its mishandling.

Upstream product

• 332013-42-0 ethyl 2-methylaminocarbonyl-4-picolinate 
• 1570-45-2 isonicotinic acid ethylester 

Downstream Products

• 332012-40-5 Telatinib 
• 332012-46-1 4-[({4-[(4-methoxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 
• 332012-57-4 4-[({4-[(3-chlorophenyl)amino]-furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 
• 1353656-38-8 4-({[6-amino-3,5-dicyano-4-(4-fluorophenyl)pyridin-2-yl]oxy}methyl)-N-methylpyridine-2-carboxamide 
• 1353657-46-1 4-({[6-chloro-3,5-dicyano-4-(3,4-difluorophenyl)pyridin-2-yl]sulfanyl}methyl)-N-methylpyridine-2-carboxamide 
• 1353656-24-2 4-({[6-amino-3,5-dicyano-4-(3,4-difluorophenyl)pyridin-2-yl]sulfanyl}methyl)-N-methylpyridine-2-carboxamide 
• 1353657-57-4 4-({[6-chloro-3,5-dicyano-4-(4-fluorophenyl)pyridin-2-yl]oxy}methyl)-N-methylpyridine-2-carboxamide 
• 1198212-23-5 4-{[(6-amino-3,5-dicyano-4-phenylpyridin-2-yl)sulfanyl]methyl}-N-methylpyridine-2-carboxamide 
• 1353656-22-0 C₂₁H₁₅FN₆OS 
• 1353656-42-4 4-[({6-amino-3,5-dicyano-4-[4-(2-hydroxyethoxy)phenyl]pyridin-2-yl}sulfanyl)methyl]-N-methylpyridine-2-carboxamide 
• 1353656-59-3 4-[({6-amino-4-[4-(2-amino-2-oxoethoxy)phenyl]-3,5-dicyanopyridin-2-yl}sulfanyl)methyl]-N-methylpyridine-2-carboxamide 
• 1353656-75-3 rac-4-[1-({6-amino-3,5-dicyano-4-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}sulfanyl)ethyl]-N-methylpyridine-2-carboxamide 
• 1353656-82-2 4-[({6-amino-3,5-dicyano-4-[4-(2-hydroxyethoxy)phenyl]pyridin-2-yl}oxy)methyl]-N-methyl-pyridine-2-carboxamide 
• 1353657-07-4 4-({[3,5-dicyano-4-(4-fluorophenyl)-6-(3-hydroxyazetidin-1-yl)pyridin-2-yl]oxy}methyl)-N-methylpyridine-2-carboxamide 

Relevant articles and documents

Design, synthesis and biological evaluation of indole derivatives as novel inhibitors targeting B-Raf kinase

A series of novel indole derivatives were designed and synthesized and their inhibitory activity against B-Raf and HepG2 cell were also described. Among them, compounds 7a and 7b exhibited excellent potency, which showed the potential for further research

COMPOUNDS FOR TREATING PULMONARY HYPERTENSION

The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.